For Consumers

FDA Office of Women's Health Update Archive

 

 

The words e-update with blue background

The Office of Women's Health e-Update highlights women's health initiatives, meetings, and regulatory safety information from the U.S. Food and Drug Administration (FDA). The e-Update is disseminated via email to the public.

Current Issue: November 2016

Message from the Director

 
During this time of thanksgiving, I want to thank the partners and individuals who have continued to share FDA health and safety information with their networks and communities. Thank you for supporting activities like our Diverse Women in Clinical Trials campaign as well as our Diverse Women in Clinical Trials Webinar Seriesdisclaimer icon. I hope you continue to look to us for resources on FDA-regulated products.
 
In November, I also want to recognize National Family Caregiver Month and American Diabetes Month. Caregiving and diabetes impact the lives of many women on a daily basis. I encourage you to visit our Tips for Caregivers webpage for information to help women manage the care of loved ones. Our Women and Diabetes webpage provides videos, publications and other tools that you can use to educate women on the safe use of FDA-approved medicines and medical devices for diabetes management. Use these important resources along with the FDA activities highlighted in this e-Update to connect with the women in your community and clinical services.
 
Marsha Henderson - Assistant Commissioner for Women’s Health
 
********************************

FDA Women’s Health Highlights

FDA approves Essure labeling with important safety information for patients and physicians.

On November 15, 2016, the U.S. Food and Drug Administration approved important labeling changes for Bayer Healthcare’s Essure permanent birth control device and completed our investigation of the trade complaint regarding allegations first made in a Citizen Petition.
 
Bayer revised the physician instructions for use and patient labeling consistent with FDA’s recently finalized guidance: Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization.
 
********************************  

FDA approves Intrarosa for postmenopausal women experiencing pain during sex.

The U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Intrarosa is the first FDA approved product containing the active ingredient prasterone, which is also known as dehydroepiandrosterone (DHEA).
 
********************************  

Caregiving Resources for Women

This Caregiving Month, visit FDA’s Tips for Caregivers webpage for resources to help caregivers manage medicines and other products for their loved ones. Celebrate all that caregivers do by sharing these tips with your family, friends and networks.
 
*********************************

Extras 

CDRH’s Patient and Care-Partner Connection

The U.S. Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) is looking for public comment on the scope and nature of a new Patient & Care-Partner Connection program, intended to build upon our efforts at conducting meaningful patient engagement.
 
********************************

FDA Meetings

December 6, 8:00 AM to 5:00PM
FDA White Oak Campus, Silver Spring, MD
********************************  

OWH Conference Exhibits

Healthy Churches 2020 National Conference
-  November 15-18, Charlotte, NC

__________________________________________________________________ 

 

Contact FDA

301-796-9440
Fax:301-847-8604
Food and Drug Administration Office of Women's Health

10903 New Hampshire Avenue

WO32-2333

Silver Spring, MD 20993

Page Last Updated: 11/18/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English